



# INTELLOTRACKER

## CRISPR in HEALTHCARE

April 2023



### ARANCA'S QUARTERLY SECTORIAL UPDATE ACROSS FOUR DIMENSIONS....





## DEVELOPMENTS

Technology/ Innovations	  	<p>US and German researchers publish study revealing new enzymatic capability of CRISPR systems, expanding potential applications beyond gene editing to include cancer therapeutics, microbial community shaping, and enhanced gene editing through counterselection.</p> <p>Source: <a href="#">News Medical Lifesciences</a></p>
New Product Launch		<p>Aldevron launched Eureka-V Nuclease, the wild-type MAD7 CRISPR Type-V nuclease, licensed from Inscripta and expands the toolkit of available CRISPR nucleases for therapeutic, diagnostic, and agricultural workflows.</p> <p>Source: <a href="#">Company News</a></p>
Technology/ Innovations	 	<p>Aix-Marseille University virologists find evidence that Pandoravirus neocaledonia evolved from smaller viruses, using CRISPR/Cas9 gene editing to study its evolutionary history. The findings, published in Nature Communications, shed light on the origins of giant viruses.</p> <p>Source: <a href="#">Scientific Literature</a></p>
Technology/ Innovations		<p>CrisprBits creates OmiCrisp, a CRISPR-based test to identify SARS-CoV2 and distinguish between Omicron and non-Omicron variants, with collaboration from C-CAMP-IndX initiative supported by the Indian Department of Biotechnology.</p> <p>Source: <a href="#">Economic Times</a></p>
Technology/ Innovations		<p>Zhengzhou University researchers have developed an easy-to-use method that uses CRISPR gene editing to detect small levels of cancer-related microRNAs (miRNAs) in exosomes in plasma and efficiently differentiate between malignant and benign samples.</p> <p>Source: <a href="#">Scientific Literature</a></p>
Technology/ Innovations		<p>Sherlock Biosciences receives US patent for Cas12 enzyme, solidifying its position as the leading CRISPR-based diagnostics provider in the US. Obtains exclusive rights from Tolo Biotech and additional IP from the Broad Institute, establishing a strong intellectual property position.</p> <p>Source: <a href="#">Company News</a></p>
Technology/ Innovations	 	<p>Researchers from USA have developed a new lipid nanoparticle with potential to deliver gene editing tools to cells in the lung. This marks a promising step in developing new, inhalable therapies for lung diseases such as cystic fibrosis.</p> <p>Source: <a href="#">University News</a></p>



## DYNAMICS

Strategic Update		<p>Editas Medicine announces strategic update, refocusing R&amp;D on hemoglobinopathies and in vivo discovery, leading to a 20% reduction in headcount to extend cash runway until 2025, prioritizing programs with high chances of technical, regulatory, and commercial success.</p> <p>Source: <a href="#">Company News</a></p>
Other Initiatives		<p>Synthego Corp introduces CRISPR Development Partners, an ecosystem of service partners including Arctoris, BrainXell, Curia, PhenoVista, and Pluristyx, offering a streamlined workflow for CRISPR-based drug development, from editing to downstream services, to accelerate the process.</p> <p>Source: <a href="#">Company News</a></p>



## DIVERSIFICATION

Licensing Activities	 	<p>Editas Medicine signs definitive agreement with Shoreline Biosciences, granting licenses for SLEEK and AsCas12a gene editing technologies and transferring preclinical gene-edited iPSC-derived natural killer cell (iNK) programs and manufacturing technologies.</p> <p>Source: <a href="#">Company News</a></p>
Mergers & Acquisition		<p>Sherlock Biosciences acquires Sense Biodetection, bolstering its go-to-market strategy with Veros™ rapid molecular test platform and manufacturing capabilities for accessible and accurate diagnostics.</p> <p>Source: <a href="#">Company News</a></p>
VC Investment	 	<p>Pre-seed funding for CrisprBits has been secured from the US-based VJ Group for \$250,000. The funding will be used towards product development, team expansion and for research and development.</p> <p>Source: <a href="#">BioSpectrum India</a></p>
Company Collaboration	 	<p>Moderna and Life Edit Therapeutics form strategic collaboration to develop in vivo mRNA gene editing therapies. The partnership combines Life Edit's gene editing technologies with Moderna's mRNA platform to target specific therapeutic goals.</p> <p>Source: <a href="#">Company News</a></p>
Licensing Activities	 	<p>Vertex Pharmaceuticals and CRISPR Therapeutics sign non-exclusive licensing agreement for CRISPR/Cas9 gene editing technology, facilitating the advancement of Vertex's hypimmune cell therapies for type 1 diabetes (T1D).</p> <p>Source: <a href="#">Company News</a></p>



## DRIVERS

Consumer Insights		<p>Victoria Gray told the Third International Summit on Human Genome Editing about the gene modification treatment she's received for sickle cell disease. Source: <a href="#">Chemistry World</a></p>
Regulatory Approval		<p>Intellia Therapeutics announced the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Innovation Passport for NTLA-2002, an in vivo genome editing candidate being developed for the treatment of hereditary angioedema (HAE). Source: <a href="#">Company News</a></p>
Regulatory Approval		<p>EMA grants approval to Vertex and CRISPR Therapeutics' gene-edited therapy exagamglogene autotemcel (exa-cel), previously known as CTX001™, an autologous, ex vivo CRISPR/Cas9 gene-edited treatment. Source: <a href="#">Thalassemia International Federation</a></p>
Regulatory Approval		<p>Vertex Pharmaceuticals announced that the U.S.FDA has approved the Investigational New Drug Application (IND) for VX-264, a fully differentiated pancreatic islet cell therapy encapsulated in a Vertex-developed immunoprotective device with the potential to treat type 1 diabetes (T1D). Source: <a href="#">Company News</a></p>
Regulatory Approval		<p>Intellia Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE). Source: <a href="#">Company News</a></p>

## SOLUTION PORTFOLIO – TECHNOLOGY RESEARCH & ADVISORY



### IP Strategy

How best can we proactively manage and monetise our technical knowhow / intellectual property?

- IP Portfolio Analysis
- IP Monetisation
- IP Valuation
- Prior Art Searches



### Technology Intelligence

How best can we keep abreast of technology trends, competitor activity and headwinds / tailwinds in our domain?

- Competitor Benchmarking
- Tech / IP Landscapes
- Technology Watch
- Market Analysis / Trends



### Growth & Strategy

Which technologies do we invest in? How do we ensure quick wins? Speed to market?

- R&D Strategy Roadmaps
- Technology Scouting
- Open Innovation
- Product Development



GROWTH ADVISORY



INVESTMENT RESEARCH & ANALYTICS



VALUATION & FINANCIAL ADVISORY



TECHNOLOGY RESEARCH & ADVISORY



PROCUREMENT & SUPPLY CHAIN INTELLIGENCE

This material is exclusive property of Aranca. No part of this presentation may be used, shared, modified and/or disseminated without permission. All rights reserved.